With cloud computing capacity growing all the time and machine learning tools coming online, marketeers’ ability to quickly and easily ask questions of the data will also increase. Learn more. Download it now!
Biosimilars have inspired cost-saving hopes in the US, provoked biopharmaceutical legal battles, and raised concerns about treatment switches. Join Jason Bernstein, Lead Strategist at Epocrates as he discusses the role of biosimilars in the evolving US biopharmaceutical landscape. Register Now
This webinar will bring together experts to offer strategies for managing the costs of developing and marketing highly specialized drugs. Join us and learn more about the growing use of specialty pharmacies and how they can be leveraged to bring costs down in drug development and marketing. Register now.
This webinar will focus on quality as a way to manage costs and create a new competitive advantage through leveraging the expertise of suppliers in providing the best combination of product and process understanding. Register Now!
During this interactive webcast Medisafe will:
• Present new patient behavior insights
• Discuss scalable implementation of AI technology for patient adherence
• Demonstrate learnings by therapeutic area, including Oncology, HIV, and Cardiology
Join us for this webinar and learn how Medidata eTMF manages all your data and content - from study planning to close - on one platform, accelerating study startup and ensuring compliance & inspection readiness. Register now!
Are you ready to comply with changes to elemental impurities guidelines? Ready or not, join Diane Paskiet and Diego Zurbriggen on October 19 at 11 a.m. ET as they discuss a comprehensive approach to elemental impurities. Register now!
Join Qlik and Dark Matter to learn how Life Science and Healthcare companies use visual big data analytics to quickly explore billions of medical claims, physician and patient data to accelerate patient recruitment and meet patient accrual goals. Register now.
The failure rate of clinical studies in depression is high, and placebo response is often blamed. In this webinar, Dr. Jack Modell, a board certified psychiatrist with more than 35 years of experience in clinical research and patient care, discusses why there is more to the story than placebo response. Register now.
Payers evaluate real-world evidence differently than regulators. Explore how RWE can help you align with payers on product environment & value vs competitors, defending product positioning, & demonstrating value. Make the most of RWE in payer negotiations to maximize your market access and success. Read more.
CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. Find out why 100% of CRO respondents report the need to unify clinical applications, including CTMS, EDC, and eTMF. Read report.
New insights just released by Medisafe show why patients say they skip doses -- and it’s not always about cost. You’ll see new adherence data by country, therapeutic area, and more. Download now.
In the quest to understand how a therapeutic intervention performs in actual use – in real medical practice outside the controlled environment of clinical trials – many life sciences organizations are stymied. They rely on one-off processes, disconnected tools, costly and redundant data stores, and ad hoc discovery methods. Download now to read more.
Attend the pharma manufacturing industry’s premier event of the year! Hear regulatory perspectives and engage in open discussions with regulators and pharma and bio-pharma industry experts. Make the most of the great networking opportunities and explore innovative products and services in our Expo Hall. Register Now!
A case of 29X increase in relative effectiveness
This webinar will benefit executives at Biotech and Pharmaceutical companies interested in growth through pipeline expansion or new products. With a change in indication, therapeutic area, dosage form, or other innovation, products developed via the US 505(b)(2) regulatory pathway gain the advantage of utilizing appropriate existing literature to meet safety and efficacy claims. But in order to be beneficial, 505(b)(2) product development must utilize an early heavy strategic approach to enable a lower cost, lower risk, and faster path to regulatory approval and market.